R ight ventricular (RV) failure (RVF) is the most important prognostic factor for both morbidity and mortality in pulmonary hypertension (PHT) but remains understudied compared with left ventricular (LV) failure. [1] [2] [3] Although some forms of pulmonary arterial hypertension (PAH) are relatively rare, overall PHT is a common clinical problem complicating LV dysfunction, chronic parenchymal lung disease, thromboembolic lung disease, as well as the peri-and postoperative care of heart/lung transplant patients.
R ight ventricular (RV) failure (RVF) is the most important prognostic factor for both morbidity and mortality in pulmonary hypertension (PHT) but remains understudied compared with left ventricular (LV) failure. [1] [2] [3] Although some forms of pulmonary arterial hypertension (PAH) are relatively rare, overall PHT is a common clinical problem complicating LV dysfunction, chronic parenchymal lung disease, thromboembolic lung disease, as well as the peri-and postoperative care of heart/lung transplant patients. 1 Thus, the need for right ventricular (RV)-specific therapies (currently unavailable) is an urgent priority. Mechanisms and therapies for LV failure cannot necessarily be extrapolated to RVF because the 2 heart chambers have critical differences in embryology and myocardial biology. 1, 2 On the one hand, the RV, which efficiently transitions from the hypertrophied RV of the fetal circulation to the thin-walled RV of the adult circulation, seems to have more plasticity in its ability to switch phenotypes. On the other hand, the RV cannot maintain an adaptive phenotype in conditions of pressure overload. Although in systemic hypertension the hypertrophied LV can maintain an adaptive phenotype and prevent clinical deterioration for decades, in PHT a short-lived adaptive compensating phase of the hypertrophied RV (cRVH) is followed by a catastrophic decompensation phase of RVH (dRVH) leading to accelerated death.
PAH or animal models of PAH (eg, monocrotaline model), where the compensatory phase is dramatically short. 2 Although some patients with PAH can respond to PAH therapies with a decrease in PA pressure, their RVs continue to deteriorate, 5 in contrast to the dogma that RV function is easily reversible when the afterload improves. These data raise the provocative possibility that there may be mechanisms, intrinsic to the RV, that drive RVF independently of the afterload. 6 We sought to determine what these mechanisms may be and speculated that they may be different than what is described in the LV. We think that there are methodological challenges in preclinical studies of this important problem in the literature. Often authors study RVH without separating between cRVH and dRVH, that is, presuming that RVH is an abnormal, diseased RV; while it is clear that cRVH is an adaptive phenotype because, although briefly, it prevents a decrease in the cardiac output (CO) and clinical symptoms. In other cases, authors may compare a relative compensated RV from one animal model (ie, the PA banding model) to a decompensated RVH (dRVH) from another model (ie, monocrotaline or Sugen/hypoxia models). Here is a problem that may arise from studies that do not systematically separate well-defined compensated versus decompensated RVs: It is well-described that RVH is characterized by a metabolic remodeling that is similar to the one seen in LV hypertrophy (LVH) and consists of a switch from oxidative phosphorylation (ie, generation of energy from the mitochondrial-based fatty acid oxidation) to a glycolytic state (ie, generation of energy from the cytoplasmic glycolysis), implying similarities to the mitochondrial suppression described in cancer (the Warburg effect). [7] [8] [9] However, it is not known whether this metabolic switch is an adaptive event or a sign of decompensation. We recently showed that when we studied the natural progression of RVF in a rat model of PAH, this metabolic switch was observed only in the cRVH (a state defined by the maintenance of CO) and lost upon entrance to dRVH (where the RV size continued to increase but the CO and survival started decreasing). 10 The glycolytic switch was associated with the activation of angiogenesis, perhaps providing the growing mass of RV myocardium with increased nutrient supply. 10 Loss of this metabolic switch was associated with decreased angiogenesis, contributing to a state of relative ischemia in dRVH and confirming clinical evidence of ischemia in RVF. 6, 11, 12 This suggests that metabolic switch toward glycolysis is a temporary adaptive state that perhaps should not be treated. We sought to determine the molecular mechanisms that underlie this phenotypic switch from cRVH to dRVH within the same animal model, as PHT progresses.
We focused on what seems to be an RV-specific axis that regulates the development of the RV, not the LV: the Islet1/myocyte enhancer factor 2 (Mef2)/Hand2 axis. 13, 14 The master transcription factor Mef2c is required for the alignment of structures and the orientation of the left-right axis during the looping of the embryo. 13, 14 Loss of Mef2c in mice results in embryonic lethality with RV morphogenetic defects, as well as vascular abnormalities. Mef2a, another member of this family, is more expressed in adult cardiac and skeletal muscle. 15 Mef2a knockout mice display increased mortality within the first week of life, with severe spontaneous right ventricular chamber dilation. 16 Mef2 has been implicated in the regulation of metabolic (pyruvate dehydrogenase kinase 4, glucose transporter 4, peroxisome proliferatoractivated receptor gamma, coactivator 1 alpha [PGC-1α]), 17 contractile (α-and β-myosin heavy chain [MHC]), 18 and angiogenic genes (vascular endothelium growth factor). 19 Moreover, Mef2 has been implicated in the regulation of microRNAs (miRNAs) that have emerged as important determinants of gene regulation in cardiac development and hypertrophy. We hypothesized that a Mef2-miRNA axis, intrinsic to RV cardiomyocytes, is driving the transition from cRVH to dRVH.
We also speculated that an external, environmental factor, such as inflammation, can be a trigger for the switch from cRVH to dRVH, perhaps explaining why RVs exposed to stronger inflammatory signals seem to fail earlier. Inflammatory cytokines such as tumor necrosis factor-α (TNF-α) are increased in the blood of patients with PAH, 20, 21 and patients with PAH that have the highest inflammation burden (eg, in scleroderma or infection with HIV) have the worst prognosis among PAH patients (without having higher pulmonary vascular resistance). 3 Inflammatory cytokines correlate positively with the severity of the disease, suggesting that they may play a direct role on RVF. 21, 22 Thus, inflammatory models of PHT, such as the monocrotaline model, are suitable for the exploration of this hypothesis. We hypothesized that an inflammatory signal may act in synergy with an RV-specific Mef2 axis activation to disturb metabolic and angiogenic signals, triggering the switch from cRVH to dRVH.
Methods
All experiments were performed with the approval of the University of Alberta Committees on Animal Policy and Welfare. Details are available in the Methods section in the Online Data Supplement. Aldrich; n=20) versus vehicle (n=10). Animals were euthanized after a comprehensive invasive and noninvasive hemodynamic evaluation, every week between 3 and 6 weeks after monocrotaline. In general, rats in the monocrotaline model appeared be compensating between third and fourth weeks after monocrotaline injection, while they enter a decompensating phase between the fifth and sixth weeks after monocrotaline with increased morbidity and mortality. However, cRVH (n=10) versus dRVH (n=10) was defined based on strict hemodynamic criteria and clinical signs as discussed in the Results section of this article.
Animal Model of RV Failure

Cardiomyocytes Isolation and Culture
Neonatal RV cardiomyocytes were isolated as previously described, 23 for transfection experiments to manipulate miRNA levels. We also isolated adult cardiomyocytes (aCMs) from compensating RVs and their corresponding LVs, in which we used infections with adenoviruses to manipulate miRNA levels; here, the isolation procedure was adapted from the study by O'Connell et al, 24 originally described for adult mice cardiomyocytes isolation.
Cell Treatments
miR-208 pre-miR mimic and anti-miR sequences, as well as negative and inhibitor-negative controls sequences (pooled in the scramble group), were purchased from Ambion (Life Technology) and were transfected in neonatal cardiomyocytes (nCM) at a final concentration of 20 nmol/L using siPORT NeoFX transfection Agent (Ambion). Adenoviruses were used at a final concentration of 400 multiplicity of infection (10 7 pfu/25 000 cells) to infect aCMs leading to infection rates of 70% to 80% in vitro after 72 hours. TNF-α and phenylephrine were dissolved in dimethyl sulfoxide and used at a final concentration of 100 ng/mL (48 hours, dimethyl sulfoxide <1:10 000) and 10 μmol/L (72 hours, dimethyl sulfoxide <1:10 000) respectively.
Statistics
Data are presented as mean±SEM. For comparison of 2 means, we used an unpaired t test. For comparison between >2 means, we used a 1-way ANOVA followed by a Tukey post hoc test. For the gene chip miRNA analysis statistical analysis, please see the TaqMan analysis section in the in the Online Data Supplement. All analyses were performed using SPSS 21 (IBM Corp). Significance P<0.05 is indicated by *, P<0.01 by **, and P<0.001 by ***.
Results
Modeling the Clinical Stages of RVF in Rat PHT
We first modeled the natural history of RVF in the monocrotaline rat model of PHT. To those studying the monocrotaline model, it is known that rats enter a phase of decompensation (developing signs of heart failure like ascites, decreased appetite and activity, decreased weight, as well as death) in the fifth to sixth week after monocrotaline injection. However, because we were interested in directly comparing tissues from cRVH versus dRVH, it was important to confirm the presence of true hemodynamic and structural signs of compensation versus decompensation. Thus, we prospectively defined criteria for compensation and decompensation, similar to what we used in our patients. Thus, dRVH was defined as a state of ongoing RVH, in which the RV systolic pressure (RVSP) decreases because of contractile failure (while the mean PA pressure remains elevated); the RV end-diastolic pressure increases; the CO decreases; clinical evidence of heart failure (ascites, decreased appetite and activity, >20% weight loss) develops; and death occurs. Our ethics committee protocol does not allow death as an end point. Because these signs of heart failure are absolute predictors of imminent death to our experience, we used this terminal morbidity as a surrogate for mortality. Thus, as soon as the rats developed these signs, we performed echocardiography and catheterization followed by euthanasia, allowing us to study all rats in the dRVH group. To study rats that would presumably have features of hemodynamic compensation, we studied them between the third and fourth week after monocrotaline injection. Here, we confirmed the presence of compensation with invasive hemodynamic assessments and echocardiography, using the parameters and clinical signs discussed above, followed by euthanasia and tissue harvest.
Thus, in our cRVH group, compared with the vehicletreated (normal) rats, we found increased mean PA pressure, RV systolic pressure, and RV weight (RV/LV+septum or RV weight/body weight), whereas the RV end-diastolic pressure remained unchanged or mildly increased and the CO remained normal or mildly decreased ( Figure 1A and 1B) . Echocardiography also showed a decrease in the PA acceleration time (a surrogate for increased mean PA pressure) but unchanged tricuspid annular plane systolic excursion (a clinically used surrogate for RV contractility), suggesting preserved RV contractility (Online Figure IA) . None of these rats showed any of the signs of terminal morbidity.
However, the dRVH rats, compared with the cRVH rats, exhibited a further increase in RV weigh; a decrease in RV systolic pressure and tricuspid annular plane systolic excursion, while the mean PA pressure remained high; a decrease in the CO; a sharp increase in RV end-diastolic pressure; and a dramatic increase in terminal morbidity (with >60% of rats developing these signs; Figure 1A and 1B; Online Figure IA) .
We then assessed cardiomyocyte hypertrophy by measuring the cardiomyocyte cross-sectional area in DAPI (4',6-diamidino-2-phenylindole)-stained sections and tissue remodeling by the degree of fibrosis measured by Masson trichrome staining. We found a 2-fold increase in cross-sectional area in cRVH compared with normal, but no further increase in dRVH, while the degree of fibrosis continued to increase ( Figure 1C ). Although the cRVH had evidence of fibrosis, there was no apparent disruption in tissue architecture, but in the dRVH there was definite distortion of tissue structure and formation of large fibrous bands. Because severe myocardial fibrosis is associated with an increase in tissue edema, 25 the progressive increase in RV weight in dRVH (without further increase in cardiomyocyte size) is compatible with edema and not ongoing myocardial hypertrophy.
The monocrotaline model of PHT is known to be associated with increased levels of inflammation. 20, 26, 27 We thus measured the level of TNF-α circulating in the serum of the rats in the different stages characterizing our model. We found increasing serum levels of TNF-α as the disease progressed toward RVF (Online Figure IB) .
Dynamic Changes of Mef2 in the Progression Toward RVF
Mef2c protein expression was increased in cRVH although it was not increased during the third week (early cRVH) but rather sharply increased in the fourth week (late cRVH); as we recorded the time of our invasive studies, we could separate them between those that had less severe PHT (third week) and more severe PHT (fourth week after monocrotaline injection; Figure 2A ). Intriguingly, the increase in Mef2c was lost again in the dRVH stage. We then studied the subcellular localization of Mef2c using immunofluorescence and found that overall the increased expression of Mef2c in cRVH coincided with its nuclear translocation ( Figure 2B ), suggesting an increase in its transcriptional activity during cRVH. This was again inhibited in dRVH. This pattern was confirmed by the measurement of the Mef2c target gene for glucose transporter 4, which followed a similar pattern of expression (Figure 2A and 2B). The proportion of glucose transporter 4 translocated to the plasma membrane (stained with a Pan-cadherin antibody) was also increased in cRVH and lost in dRVH (Online Figure IIA) . These data show that the fetal factor Mef2c is transiently increased only in cRVH, contributing to the adaptive nature of this stage, perhaps similar to the physiological RVH of the fetal circulation in utero. This transient increase in glucose transporter 4 is in keeping with our recent findings that increased glucose uptake (measured by micro-positron emission tomographycomputerized tomographic imaging in vivo) characterizes cRVH, but it is lost during dRVH. 10 We then studied the adult isoform of this transcription factor, that is, Mef2a. We found a pattern of expression that was opposite to that of Mef2c during cRVH, that is, Mef2a expression was decreased early on during cRVH (Online Figure II) . However, Mef2a failed to increase again to the levels of the normal RV (nRV) and remained downregulated during dRVH. This pattern was confirmed by the levels of the Mef2a target gene for PGC-1α that followed a similar expression pattern (Online Figure II) . Modeling the natural history of right ventricular (RV) failure in rat pulmonary hypertension (PHT). A, Normal rats and monocrotaline-induced pulmonary arterial hypertension (PAH) rats were studied with comprehensive hemodynamic assessment during the compensated (cRVH) and decompensated (dRVH) stages of RV hypertrophy (RVH; mean data). The cRVH stage was characterized by increased mean pulmonary artery pressure (mPAP) and RV systolic pressure (RVSP), a mild increase in RV end-diastolic pressure (RVEDP) and a preserved cardiac output (CO), as well as increased RV weight (measured by the ratio of RV over left ventricle [LV]+septum or RV over body weight [BW] ). These rats have no evidence of clinical signs of heart failure. The dRVH stage was characterized by a significant decrease in the RVSP (while mPAP remained elevated) compatible with contractile failure, a sharp increase in the RVEDP and a decrease in the CO. These rats also had clinical evidence of heart failure with the presence of ascites, decreased activity and appetite, and >20% weight loss occurring in 60% of them. n=10 rats/group, *P<0.05, **P<0.01, and ***P<0.001. B, Representative right atrial (RA), RV (black), and pulmonary arterial pressure (PAP, red) traces recorded as the catheter was advanced through the jugular vein to the RA, RV, and main pulmonary artery. In the window, the arrow is showing the site of RVEDP measurement. C, Representative differential interference contrast (DIC) pictures (nuclei in blue stained with DAPI) of RV tissues with cardiomyocytes in a cross-sectional view. Masson trichrome staining of RV tissues is shown, with keratin and muscle fibers stained in red, collagen in blue, and nuclei in black. Mean data of RV cardiomyocytes cross-sectional area (πr 2 ) were calculated to assess cardiomyocyte hypertrophy in cRVH and dRVH, compared with normal RV (nRV; n=3 rats/group, 3 random images per rat, n≈50 cardiomyocytes/group). The Fibrotic grade was calculated following the Ashcroft scale (n=5images/rat in 5 rats/group, *P<0.05, **P<0.01, and ***P<0.001). January 2, 2015 miRNA Signature of RV Failure
Although the levels and function of Mef2 are known to be regulated by specific miRNAs in LVH, we first wanted to perform an unbiased screening of miRNAs in our model because miRNA expression has not been previously studied in RVH and RVF progression within the same animal model. Although we were interested mostly in the differences between our well-defined cRVH and dRVH stages, we also studied fetal RVs (fRV) and nRV. This was because the transient expression of Mef2c in cRVH suggested a transient reactivation of a fetal RVH program. We obtained free wall tissues from fRVs (obtained immediately after birth, when the fetal circulation and fetal RVH are present) and RVs from the adult rats in which we performed the hemodynamic studies shown in Figure 1 .
We performed an unbiased screening using TaqMan LowDensity Arrays (Applied Biosystems) to determine the expression of the 377 well-characterized miRNAs included in the array. We used several filters and 3 separate standard normalization procedures, as described in Methods section of this article. To assess the variability between samples, we used a hierarchical clustering analysis (Online Figure III) , where each column represented 1 sample and each row the profile of expression of 1 miRNA, and a principal component analysis (PCA, as described in Methods in the Online Data Supplement; Online Figure IVA ). fRVs were clearly separated from all other samples on PCA1, the principal level of variability (fRV PCA1 ≈−300, nRV/cRVH/dRVH PCA1 ≈50), suggesting a specific and strong fRV miRNA program. Although this program was not reactivated in full in the adult RVH stages, we observed several miRNAs that were re-expressed in RVH. Although we observed an overlap between cRVH and dRVH on PCA2, the second level of variability, those 2 groups were separated from nRV in terms of miRNA profiles (nRV PCA2 ≈80, cRVH PCA2 ≈−50 overlapping with dRVH PCA2 ≈−80). To study differences among nRV, cRVH, and dRVH, we performed an adjusted ANOVA with a Benjamini-Hochberg correction on the fold changes among groups (ie, nRV versus cRVH, nRV versus dRVH, and cRVH versus dRVH), using again 3 different normalization procedures, based on U6, median, and quantile corrections. We found 14 miRNAs that were differentially expressed after all 3 normalizations, achieving statistical significance by all (Online Figure IVB) . Among them, we were interested in the 6 that showed a different pattern of expression compared with what is known based on published data on LVH or they had not been previously described in LVH models (highlighted in grey in Online Figure IVC) : miR-200b, -338-3p, -328, -155, 28 -92a, and -208a. 29, 30 Based on the TargetScan (http://www. targetscan.org/) and DAVID 31 (http://david.abcc.ncifcrf.gov/) databases (which describe pathways that might be perturbed by changes in the level of specific miRNAs), these 6 miRNAs are strongly implicated in angiogenesis, cytoskeleton, and p53 pathways, in keeping with previously published reports on RVH. 10, 32 The mean data from the arrays for these miRNAs are presented in Online Figure IVD and IVE, showing the progressive decrease in the levels of miR-200b, -208a, -92a, -328, -338-3p, and the progressive increase of 155, as RVF progresses.
We focused on miR-208a for the following reasons: 1. It is a myocardium-specific miRNA, suggesting that if measured in the serum it could potentially be a good biomarker of the molecular state of RVH, allowing one to follow an RV-specific (as the LV is mostly normal in most PHT syndromes) miRNA signature compared with the circulating miRNA changes reflecting the remodeling of pulmonary vessels or peripheral tissues in PHT. 2. It is hosted by the αMHC gene, and cardiac hypertrophy is characterized by a switch from αMHC to β-isotype in cardiomyocytes, 33 possibly through Mef2 activation. 18 3. Its expression has been shown to be maintained in the progression from normal LV to LVH to LV failure, 34 and thus the observation that its levels decreased during RVF progression would suggest a chamber-specific regulatory mechanism.
We confirmed the progressive decrease in miR-208 in cRVH and dRVH compared with nRV by individual quantitative realtime-polymerase chain reaction in the rats studied in Figure 1 , this time using a much larger sample size than the n=3 that we used for the screening TaqMan low-density array experiments (ie, n=10/group) ( Figure 3A) . miR-208 levels were also found to negatively correlate with indexed RV weight ( Figure 3A ; r=−0.72; n=20; P<0.001). To determine whether miR-208 could be a serum-based biomarker of the molecular state of RVH, we measured miR-208 level in the serum of nRV, cRVH, and dRVH rats (n=3 nRV, 9 cRVH, and 9 dRVH). We detected miR-208 in the late cycles of quantitative real-time-polymerase chain reaction amplification (Ct=37), a fact compatible with its known low levels in the serum, whereas the Ct of our housekeeping gene (U6) was 27, suggesting that there was no significant degradation during our storage and isolation procedures. To ensure that our measurements were within the linear dynamic range of our assay, we also performed a dose-response with a miR-208 mimic and confirmed that our measurements were indeed within the linear range (Material in the Online Data Supplement and Online Fig. VA) . We found a decrease in the serum levels of miR-208 during progression toward RVF ( Figure 3B ; Online Figure VA ), suggesting that circulating levels of miR-208 might represent what is happening in RV myocardium. As mentioned above, miR-208 is hosted by the αMHC gene, known to be inhibited in cardiac hypertrophy in favor of the βMHC gene. We confirmed that αMHC is downregulated in cRVH and further dowregulated in dRVH and that βMHC expression follows the exact opposite pattern ( Figure 3C ). This correlation of molecular and physiological features of the 3 stages of RV function presented in Figure 1 further strengthens our model of natural and correlation between miR-208 expression and the progression of the disease assessed by the ratio RV weight/body weight (BW). B, Circulating (serum) miR-208 levels measured by qRT-PCR in RNA extracted from sera in normal, compensated RV hypertrophy (cRVH), and decompensated RV hypertrophy (dRVH) rats. C, α-and β-myosin heavy chain (MHC) mRNA levels measured in RV free wall tissues and (D) correlation between miR-208 levels (from B) and αMHC mRNA levels. For A-D, n=3 normal RV (nRV), 9 cRVH, and 9 dRVH; *P<0.05, **P<0.01, and ***P<0.001.
history of RVF in the rat. Moreover, we found a strong correlation between αMHC and miR-208 levels in the hypertrophied RV myocardium (Figure 3D ; r=0.72; n=20; P<0.001), supporting that miR-208 downregulation is subsequent to the inhibition of its host gene (ie, αMHC).
The subunit MED13 of the complex mediator of transcription has been identified as miR-208 direct target gene in the heart. 34 Interestingly, another miRNA of our short list, miR200b, is also able to target MED13 (Online Figure VB) and has a similar pattern of expression with miR-208, that is, it is decreasing while RV weight increases (Online Figure VC and VD; r=−0.64; n=3 nRV, 9 cRVH, and 9 dRVH; P<0.001). Both miR-208 and 200b have binding sites in the MED13 3′ untranslated region (Online Figure VB) and thus their decrease may lead to an increase in the expression of the MED13/nuclear receptor corepressor 1 (NCoR1) transcription complex. This complex is critical for many metabolic and angiogenic genes, and also the regulation of Mef2 function itself, via negative feedback loops, 35 ,36 as we discuss below.
MED13 Expression Is Upregulated in dRVH
MED13 is known to act as a functional bridge between nuclear receptors bound to DNA 37 and the basal transcription apparatus, including RNA polymerase II. 38 It has been identified as a negative regulator of metabolism through repressive effects on nuclear receptor activity and subsequent downregulation of a package of metabolic genes. 35 We speculated that changes in MED13 expression could explain why at some point the adaptive metabolic response seen in cRVH is switched off in dRVH, leading to failure. We thus measured the mRNA level of MED13 in our model and found that MED13 mRNA expression is indeed increased in dRVH (Figure 4) . To specifically study protein expression in RV cardiomyocytes, we used immunostaining and found a similar pattern with a significant increase in the percentage of cells with nuclear MED13 in dRVH compared with either cRVH or nRV (Figure 4) .
Exploring the role of this first description of MED13 activation in RV failure, we studied its transcriptional partner NCoR1. 35 NCoR1 N-terminal domains recruit histone deacetylases (including class I [HDAC3] and II [HDAC4]), 39, 40 resulting in hypoacetylation of histones and a chromatin structure resistant to transcription. NCoR1 knockdown has been associated with a robust increase in muscle mitochondria number and activity, 36 mainly through increased transcription, acetylation and activity of Mef2 family members, and increased transcription Figure 4 . Complex mediator of transcription 13 (MED13) expression is upregulated in decompensated right ventricular (RV) hypertrophy (dRVH). MED13 and nuclear receptor corepressor 1 (NCoR1) mRNA levels measured by quantitative real-timepolymerase chain reaction in normal RV (nRV), compensated RV hypertrophy (cRVH), and dRVH RV free wall tissues. Representative photomicrographs of RV tissues immunostained for the detection of NCoR1 in red, MED13 in pink, and colocalizing with nuclei stained in blue with DAPI. Cardiac cells were identified using a cardiac myosin heavy chain (MHC) staining (green). Mean data from the images show the percentages of cells with a positive nuclear staining for either MED13 or NCoR1 (magnified images shown to the right). n=5 images/ rat in 5 rats/group; *P<0.05, **P<0.01, and ***P<0.001.
of metabolically regulated genes including pyruvate dehydrogenase kinase 4, and VEGF. 36 We previously showed that pyruvate dehydrogenase kinase 4 and vascular endothelium growth factor expressions were increased in cRVH and decreased in dRVH, 10 an observation that could potentially be explained by NCoR1 activation. We measured NCoR1 mRNA level in our model and found that NCoR1 expression was slightly decreased in cRVH but significantly increased again in dRVH (Figure 4) . We measured NCoR1 protein expression and localization by immunostaining and found a decrease in the percentage of cells with nuclear NCoR1 in cRVH compared with nRV, but then a 4-fold increase in dRVH compared with cRVH ( Figure 4) . We also evaluated NCoR1 activity using the acetylation status of histones 3 and 4, both known nuclear targets of NCoR1. 41, 42 We found that histones 3 and 4 acetylation is upregulated in late cRVH and downregulated in dRVH, in keeping with NCoR1 expression (Figure 5A and 5B). Although these immunoblot data reflected changes in the whole RV tissue, localizing the signal with acetylated histones 3 immunostaining in RV cardiomyocytes allowed us to confirm the upregulation in cRVH and a more robust inhibition in dRVH myocardium ( Figure 5A ).
miR-208 and Inflammation Regulates the MED13/NCoR1-Mef2 Axis in the RV but not in the LV
To study whether the miR-208 downregulation is indeed directly responsible for our observed increase in MED13 expression, we performed mechanistic studies using 2 in vitro models: 1 in normal nCM and 1 in aCMs from hypertrophied RVs. We had found that the expression of miR-208 progressively decreased from its levels in nRVs as RVF developed ( Figure 3B ). We therefore first studied the effect of miR-208 modulation in normal nCM from RVs and corresponding LVs, cultured and transfected with either mimic or anti-miR-208. We found that a similar decrease of miR-208 (80% decrease; Figure 6A ) in LV and RV cardiomyocytes was associated with a particularly strong increase in MED13 expression in RV (10-fold increase) compared with LV cardiomyocytes (4-fold increase; Figure 6A ). This increase in MED13 expression in RV cardiomyocytes was associated with NCoR1 upregulation and Mef2 downregulation, whereas no changes were measured in LV cardiomyocytes. In contrast, no changes were found after miR-208 upregulation in this model, in either LV or RV cardiomyocytes ( Figure 6A ). This suggested that perhaps these normal cells from both ventricles express enough miR-208 at baseline to inhibit MED13 and that further increase in its levels has no effect, while the RV is much more sensitive to a decrease in miR-208 than the LV.
Using the UCSC genome browser (online genome browser hosted by the University of California, Santa Cruz at http://genome.ucsc.edu/), we found nuclear factor κB-binding sites (V$NFKAPPAB_01) on the MED13 (in blue) promoter (Online Figure VI) , suggesting a possible direct regulation of the MED13/NCoR1 axis by inflammation and TNF-α, a cytokine that is upregulated in the serum of PAH patients and in our rat model (Online Figure I) . We thus stimulated normal Figure 5 . Right ventricular (RV) myocardium histone acetylation during RV hypertrophy (RVH) progression. Levels of acetylated versus total histones 3 (H3; A) and H4 (B) histones measured by immunoblots are shown to assess the nuclear receptor corepressor 1 (NCoR1) deacetylase activity. Mean data correspond to the ratio of acetylated versus total versus actin expression (used as loading control). n=3 rats/group; *P<0.05, **P<0.01, and ***P<0.001. Representative photomicrographs of RV tissues immunostained for the detection of Ac-H3 in red, colocalizing with nuclei stained in blue with DAPI. Myocardial cells were identified using a cardiac myosin heavy chain (MHC) staining (green). A magnified image is shown to the right. The percentages of cells with a positive nuclear staining for Ac-H3 were calculated. n=5 images/rat in 5 rats/group; *P<0.05, **P<0.01, and ***P<0.001. cRVH indicates compensated RV hypertrophy; dRVH, decompensated RV hypertrophy; and nRV, normal RV. nCM with TNF-α for 48 hours and found a 3-fold increase in MED13 expression in RV but not LV cells ( Figure 6B ). This suggests a possible RV-specific regulation of MED13 by TNF-α contributing, along with the miR-208 downregulation, to the transition from cRVH to dRVH in a chamber-specific manner.
We then studied the effects of miR-208 modulation in our second model of aCMs from normal and cRVH hearts to determine whether we can recreate the dRVH phenotype (in terms of the MED13-NCoR1-Mef2 axis) in vitro. We first studied the effect of miR-208 downregulation in normal aCMs obtained from the RV and corresponding LV free walls (aCM). Because transfection is not an efficient method for gene delivery in aCMs (in contrast to nCM), we used an adenovirus (10 7 pfu/ mL, 72 hours) coding for an anti-miR-208 sequence (Ad-antimiR-208). aCM were infected for 72 hours, and the percentage of infected cells was determined using green fluorescent protein (GFP), coexpressed by the virus. We also used a GFP-only adenovirus as control (Ad GFP). After 72 hours, 80% of cells were expressing GFP with a good survival of aCM ( Figure 7A ). Once again, we found that decreased expression of miR-208 was associated with a much higher increase in MED13 expression in RV compared with LV aCM, despite a similar downregulation of miR-208 ( Figure 7B ).
We then speculated that in cRVH aCM (where the levels of miR-208 are already decreased compared with nRV), a decrease in miR-208 and an increase in TNF-α may cross a threshold that would trigger the entrance to dRVH. As in neonatal normal cells, TNF-α induced a 2-fold increase in MED13 mRNA level in cRVH aCM, whereas no effect was noticeable on the corresponding LV aCM ( Figure 7C ). This response was again associated with an increase in NCoR1 mRNA level in cRVH aCM ( Figure 7C ). Infection with Ad-anti-miR-208 (10 7 pfu/mL, 72 hours) caused an increase in NCoR1 mRNA levels and a 2-fold decrease in Mef2 mRNA levels, mimicking the transition to dRVH in vivo ( Figure 7D ). TNF-α in combination with the Ad-anti-miR-208 increased the effects of miR-208 inhibition on NCoR1 mRNA levels, resulting in about a 4-fold increase. We found a 2-fold decrease in vascular endothelium growth factor mRNA levels (another direct target of NCoR1) after infection with Ad-anti-miR-208 and a 3-fold decrease after the combination of Ad-anti-miR-208 and TNF-α ( Figure 7D ). We then measured the expression level of Mef2, and we found that the inhibition of miR-208 significantly decreased the expression of Mef2. However, in contrast to a potential synergistic effect between miR-208 and TNF-α on NCoR1 and thus on Mef2 function, the addition of TNF-α on top of anti-miR-208 did not have synergistic effects on Mef2 expression. Interestingly, compared with the empty virus, Adanti-miR-208 increased Mef2 expression ( Figure 7D ).
These data suggested that in contrast to the LV, there is a progressively decreasing level of miR-208 in RVH but perhaps a second trigger (ie, inflammation) is needed for enough MED13/NCoR1 upregulation and Mef2 suppression. This suppression of Mef2 has a potentially dual basis: an inhibition of its activity because of the NCoR1-mediated effects on Mef2 acetylation and an inhibition of its transcription, potentially because of the previously described effects of NcoR1 acetylation on the Mef2 promoter (in addition to the acetylation of Mef2 protein itself). 36 As data in Figure 2A and 5A had shown, the expression of Mef2 in late cRVH and its loss in dRVH coincide with the increase in acetylation in late cRVH and its suppression again in dRVH, likely mediated by NCoR1.
In the setting of a sustained increase in the afterload, this inhibition of Mef2 activity/expression may push the RV cardiomyocytes away from a normal/compensatory phenotype toward failure. To further study this hypothesis, we studied aCM shape (cross-sectional area and length) under hypertrophic stimuli using a 3D reconstruction with the cellular planes scanned in the z axis on a confocal microscope (Figure 7E ), Figure 7 . miR-208 downregulation and tumor necrosis factor-α (TNF-α) drive the transition from compensated right ventricular (RV) hypertrophy (cRVH) toward decompensated RV hypertrophy (dRVH). A, Percentage of infected cells and representative pictures of isolated adult rat cardiomyocytes (aCM) infected with an adenovirus expressing GFP and cultured for 72 hours. The percentage of GFP-positive cells is >80% confirming effective infection rates. B, miR-208 and MED13 mRNA levels measured by quantitative real-time (qRT)-polymerase chain reaction (PCR) in aCM isolated from the free wall of the normal RV (nRV) and left ventricle (LV) infected with an adenovirus expressing an anti-miR-208 sequence or its control expressing only GFP. Note that while the degree of miR-208 inhibition is similar in the nRV and LV cells, the increase in MED13 levels is significant only in the nRV cardiomyocytes. C, MED13 and nuclear receptor corepressor 1 (NCoR1) mRNA levels measured by qRT-PCR from aCM isolated from cRVH and corresponding LV (from the same rat) cultured and stimulated with TNF-α (100 ng/mL) for 72 hours. Note that MED13 and NCoR1 expressions are increased only in the cRVH cardiomyocytes. This increase in the cRVH cardiomyocytes makes them similar to the dRVH cardiomyocytes, which are characterized by higher levels of MED13 and NCoR1 (see Figure 4) . D, aCM from cRVH free walls (versus aCM from their corresponding LV free walls from the same rats) were treated with either an adenovirus expressing an anti-miR-208 sequence alone or in combination with TNF-α. NCoR1, vascular endothelium growth factor (VEGF), and myocyte enhancer factor 2 (Mef2) mRNA level were determined by qRT-PCR. Note that the anti-miR-208 inhibition and TNF-α increased the NCoR1 levels only in cRVH cells and decreased its target (VEGF) and Mef2 levels in a chamber-specific manner. A-D, n=3 experiments/group, *P<0.05, **P<0.01, and ***P<0.001. E, Representative confocal images of adult cardiomyocytes 3D reconstructions in their y and z axis. F, Cross-sectional area (CSA), length, and volume of aCM isolated from nRV free wall (versus aCM from their corresponding LV free wall) measured by 3D reconstruction. aCM hypertrophy was stimulated using phenylephrine, and aCM were treated with an adenovirus expressing GFP or an anti-miR-208 sequence. Inhibition of miR-208 caused a decrease in the CSA of hypertrophied aCM from the RV but not the LV and increased their length, while the volume remained constant, suggesting aCM dilatation. n=20 aCM/group, *P<0.05 and ** in a manner similar to what has been published in LV aCM. 43 As expected, phenylephrine (10 μmol/L) increased the crosssectional area in both LV and RV aCM compared with control cells ( Figure 7F ). However, this response was attenuated with the addition of Ad-anti-miR-208, suggesting that the phenylephrine-induced aCM hypertrophy was inhibited by the decrease in miR-208. At the same time, Ad-anti-miR-208 infection caused an increase in RV (but not LV) aCM length, whereas the volume of the cells remained constant (Figure 7F ), compatible with a dilated cardiomyopathy state. 44, 45 
Discussion
Here, we show for the first time a critical role of a miR-208/ Mef2 axis in RVF. Although it has been well-known that Mef2 is critical to the development of the RV specifically, this has not been studied in models of RV failure in PHT. The use of carefully defined stages of the natural history of RVF within the same animal model using clinically relevant criteria of cRVH versus dRVH ( CO, RV contractility, RV end-diastolic pressure, clinical signs) allowed us to describe a potential RV-specific molecular trigger for the entrance to dRVH. In contrast to what is known in LVH, the levels of miR-208 (a myocardium-specific miRNA) continuously decrease as RVH progresses, eventually (and particularly in the presence of inflammation) allowing the repression of Mef2 and the exit from a fetal-like compensatory phase (Figure 8 ). The presence of feedback loops (eg, Mef2 inhibits miR-208 expression by regulating its host αMHC gene, which in turn inhibits Mef2 expression and activity via the MED13/NCoR1 complex) is characteristic of mechanisms that need fine tuning and careful regulation during development, such as the Mef2 axis. Our finding that inflammation (TNF-α) could also serve as a second hit for the entrance to dRVH, in synergy with the decreasing miR-208 (Figure 8 ), can potentially explain why RVs exposed to strong inflammatory environments are much more prone to decompensation. We showed for the first time that TNF-α, in contrast to miR-208 that inhibits it, activates the MED13/NCoR1 axis, potentially through nuclear factor κB-mediated effects on the MED13 promoter and preferentially on the RV compared with the LV cardiomyocytes ( Figure 8) .
Another novel aspect of our data is the unbiased discovery of an RV-specific miRNA signature that marks the entrance to the decompensating phase of RV function. It was through this short list of miRNAs that we chose to study the specific role of miR-208 in RVF. We enhanced the mechanistic aspect of our data by studying in vitro models in parallel to the in vivo models of RV decompensation. Considering the limitations of gene manipulations in cardiac myocytes in vitro, we used a model of neonatal RV cardiomyocytes and a model of aCMs from normal and cRVH RVs to show that decreasing the levels of mir-208 caused an increase in the Med13-NCoR1 axis repressing Mef2. We specifically showed that further decrease of miR-208 in cRVH myocardial cells by anti-miR-208 along with TNF-α stimulation allowed the repression of Mef2, marking the entrance to the dRVH as our in vivo data showed. This is important because, being myocardium-specific and measurable in the serum (Online Figure I ; Figure 3C ), miR-208 can potentially be a biomarker that along with the levels of TNF-α (or potentially other cytokines that activate nuclear factor κB) could provide serum-based signatures that may correlate with the RV phenotype in vivo and also predict the RVs more likely to fail.
Serum miR-208 has been shown to be a potential biomarker in patients with myocardial infarction, as its levels are increased compared with those from healthy patients. [46] [47] [48] On the contrary, some authors have failed to detect serum miR-208 in healthy patients, raising concerns whether this will be of practical value. 49, 50 However, in these studies, relatively small number of patients were studied and not enough details were given to determine whether there was RNA degradation or methodologic differences among studies. Certainly, because miR-208's only source is one organ (the heart), its serum levels are low, posing challenges in terms of optimal conditions of RNA isolation and prevention of its degradation for future larger studies. However, its specificity in the case of RVF may be particularly high, given Figure 8 . Myocyte enhancer factor 2c (Mef2c)/miR-208 axis drives the transition from a compensated right ventricle (RV) to a decompensated RV within a self-limiting feedback loop. Schematic representation of molecular mechanisms implicating the miR-208/Mef2c/complex mediator of transcription 13 (MED13)/nuclear receptor corepressor 1 (NCoR1) axis in RV failure (RVF): As RV hypertrophy (RVH) progresses in response to increasing afterload, the levels of miR-208 in the RV cardiomyocytes (and the serum) decrease while the tumor necrosis factor-α (TNF-α) levels (in the serum) increase in the rat monocrotaline model (which resembles inflammatory pulmonary hypertension [PHT] syndromes like the ones in patients with idiopathic pulmonary arterial hypertension [PAH] or scleroderma). Mef2c is activated during the compensatory phase, likely as part of an activation of a fetal gene program and mechanotransduction signaling because of pressure overload. Mef2c is a key factor in the metabolic angiogenic and contractile adaptation of RV to pressure overload. However, Mef2c is likely responsible for an RV-specific downregulation of miR-208 (since by inhibiting its target gene α-myosin heavy chain (MHC), which hosts miR-208, will also decrease miR-208 levels). This progressive downregulation of miR-208 along with the increasing effects of TNF-α, eventually increases the expression of MED13 and the subsequent recruitment of NCoR1, enough to subsequently inhibit Mef2c (both its expression and activity because of deacetylation of the Mef2c protein and its promoter). This limits the ability of Mef2 to promote compensation, leading to an inhibition of a package of metabolic and angiogenic genes that characterize the compensated RVH (cRVH) phenotype, triggering the entrance of RV cardiomyocytes into a decompensated phase. This model supported by our data suggests a novel RV-specific model of heart failure, combining both intrinsic molecular programs (miR-208) and environmental triggers (inflammation). GO indicates glucose oxidation.
the fact that the left ventricle in these patients is typically normal. miR-208 will not be of value as a biomarker to diagnose RV disease (in other words normal versus RV disease patients) because there are plenty of ways to diagnose RV disease easily and reliably, including physical examination alone. But in the setting of a cohort of patients with PAH, in which baseline levels are measured and miR-208 is detectable, decreasing levels over time (versus sustained levels) may identify early the patients that may be declining clinically later on.
Another important aspect of our work is that the synergy between miR-208 and TNF-α on RV cardiomyocytes did not take place in LV cardiomyocytes. Along with the critical role of Mef2 in RV development, our work suggests that there may indeed be an RV-specific mechanism for heart failure. Although its existence has been suspected, we think this may be the first time that a potentially RV-specific mechanism of heart failure is elucidated.
The description of stage-specific clinical and molecular phenotypes in RVH may guide the development of stage-specific therapies. For example, most patients with PHT are diagnosed at late stages because of the absence and nonspecificity of symptoms at early stages of the disease. At best, a patient with PHT is diagnosed during a compensating, that is, cRVH, stage. In addition to the therapies that may aim to reverse the pulmonary vascular disease, what will be important for this patient are therapies that will prevent the entrance to a decompensation phase (ie, dRVH). Our work suggests that therapies that will increase the expression of miR-208 and decrease inflammation will be beneficial. However, it is difficult at this point to pragmatically envision gene therapy trials promoting miR-208 in a chamber-specific manner. However, mimicking the effects of miR-208 upregulation, that is, inhibiting the MED13/ NCoR1 axis, may be easier pharmacologically. For example, one of the major ways that the MED13-NCoR1 axis exerts its molecular effects on nuclear factors is through histone acetylation. There is great interest in the use of HDAC inhibitors in the treatment of heart failure. Some work has been published on the role of HDACs in PHT and RVH or RVF syndromes, although at this point most of the HDACs used (such as valproic acid or trichostatin A) 51, 52 have well-characterized pleiotropic effects and regulate multiple mechanisms beyond histone acetylation. Although it is also difficult to separate in vivo the effects of these drugs on the pulmonary vasculature versus the RV myocardium, our work suggests that their efficacy may depend on the exact stage of the disease in which they are given. For example, HDACs inhibitors (which will promote acetylation of histones, antagonizing the enhanced MED13/NCoR1 axis) may prevent the entry to a dRVH stage (where acetylation is decreased) but they will not reverse a cRVH toward an nRV phenotype because acetylation is already increased in cRVH. Causing a switch toward a nRV phenotype may be an undesirable effect if the afterload (ie, pulmonary vascular remodeling) is not decreased at the same time. Thus, we think our work may help clarify some of the conflicts in the literature on the role of HDAC inhibitors in RV disease in the future. 51, 52 Two other studies have reported miRNA changes in RVH models, one in the pulmonary artery banding model and another in a study comparing RVs from the PA banding model with
RVs from a PHT model (Sugen+hypoxia). Several miRNAs were reported altered in these studies, whether upregulated miR-34 and -21 and downregulated miR-1 53 in the first study, or downregulated miR-1 and -133 in the second. 32 Although in our unbiased screening studies using miRNA microarrays we found a similar expression pattern in those miRNAs during progression toward failure (Online Figure VII) , we failed to identify them as markers of a specific stage of the disease, based on our rigorous definition of RV disease stages. The sensitivity of miRNA levels to precise experimental conditions/ models and the variety of filters/controls used to expose significant differences may explain the variability of data among reports, a rather frequent (and perhaps unfortunate) observation in the miRNA literature. We think that the precise definition of the different RVH stages within the same RV model and the vigorous control/filter procedures that we followed strengthen our data and may facilitate efforts by others to replicate our data. Although our study used different models and analysis compared with these 2 studies, we cannot help but observe that miR-1 and miR-133 are also known to be musclespecific (skeletal and cardiac) and both have been shown to be downregulated in the hearts of mice lacking Mef2. 54 miR-1 and mir-133 are coded by bicistronic clusters, and several Mef2 enhancer sequences were identified upstream and intragenic of the miR-1 and 133 loci. 54, 55 We also note that our data (Online Figure II) are in agreement with another study that reported a downregulation of PGC-1α (a product of Mef2) in RVs from rats 4 weeks after monocrotaline injection. 56 There is also evidence of Mef2 activation after focal adhesion kinase activation, 57 a well-known mechanotransductor activated during pressure overload stages. 58 Thus, Mef2 could be implicated in the regulation of miR-1 and miR-133, as well as PGC-1α in addition to miR-208, perhaps emphasizing the importance of the inhibition of Mef2c during dRVH, featured in our work.
Limitations of our work include the lack of causal evidence for the role of the Mef2c/miR-208/MED13/NCoR1 axis in vivo, although previous studies, as discussed, have confirmed a critical role of the Mef2 axis in RV development and function. Although the changes that we described in the RV tissues from our RVH stages are associative, we think that our mechanistic in vitro experiments support the importance of our proposed mechanism. Specifically, the effects of miR-208 inhibition causing dilatation of hypertrophied RV aCM, while they did not have an effect on the LV (Figure 7F ), are supportive of a causal effect of the miR-208 inhibition for dRVH and RVF.
Although the strength of our study was that the definition of the RV function stages was based on objectively measured hemodynamic criteria, a limitation of may be the potential confounding by temporal factors; that is, changes dependent on time after monocrotaline, not necessarily related to myocardial decompensation, that may have affected the morbidity of our rats. In addition, this work would have been strengthened by the description of similar changes in the Mef2c/miR-208/ MED13/NCoR1 axis in human RV tissues. However, the supply of tissues from RVs that have been carefully phenotyped (eg, with hemodynamic, clinical, and imaging data) to categorize them as cRVH versus dRVH is particularly challenging. Nevertheless, the potential for the detection of miR-208 and
